Two-hundred biotech allies from more than 40 different states visited Washington D.C. this week. These advocates met with policymakers on Capitol Hill and in the administration to share BIO’s vision and policy priorities for a strong biotech industry. When it came to the topic of prescription drug…

This year the Biotechnology Innovation Organization (BIO) celebrates our 25th anniversary. It’s impossible to review BIO’s interactive historical timeline without reflecting with pride on the role we’ve played in shaping policy to save lives and promote the health of our planet. So much of our…

Today marks an important day for America. It was just one year ago that the revolutionary 21st Century Cures Act was signed into law – a piece of legislation crafted to accelerate the discovery, development, and delivery of new cures and treatments. And while it’s not every day in Washington that…

Disease is an equal-opportunity enemy. It strikes men and women; children and seniors; and people of every race, ethnicity and nationality. It’s hard to imagine an industry with a more diverse customer base than the biotechnology companies creating next-generation cures for patients around the…

While in Boston this week, BIO CEO Jim Greenwood sat down with Bloomberg Boston Bureau Chief Tom Moroney to discuss some of the big issues facing the healthcare industry, including drug pricing, healthcare reform and how biomedical innovation can help solve the opioid crisis. Jim’s segment comes on…

In his column, the New York Times’s Nicholas Kristof’s does a disservice to the millions of men and women who have dedicated their lives to developing new cures and treatments for the world’s most devastating diseases. To equate their work to drug pushers is demeaning and out of bounds. Mr…

The scourge of opioid abuse is a growing public health crisis that has left no community in our nation untouched. It cuts across geographic, generational, political and economic divides, leaving in its wake countless victims, devastated families and economic ruin. America’s biopharmaceutical…

As CEO of a global organization, I’m often on the run. To maintain my stamina, I try to work out as often as my schedule allows. Given how proud and exhausted I am after logging in a solid hour on the weights or the treadmill, I’ve always been flabbergasted at contemporaries who can finish a…

Today is World Hepatitis Day. In The Hill newspaper, BIO CEO Jim Greenwood argues that insurers should not be penny-wise and pound-foolish by refusing to cover new miracles cures for hepatitis C, the leading cause of liver cancer and liver transplants in the United States. Instead of coming up with…

Under a pending bill in California, drug companies would be required to disclose confidential and sensitive business records and detailed data about drug development costs. This bill represents a degree of government intrusion into a free market industry that is without precedent. Senate Bill 17…